SYRE

Spyre Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$102.91

Price (1 Year)

$106.49 $30

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30
Non-compliant assets / Total market cap %45.7 / %30
Non-compliant revenue / Total incomeNo data

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).

Website

Analysis (Turkish): SYRE Hissesi Caiz mi, Helal mi? Spyre Therapeutics, Inc. Katılım Analizi